圣诺生物部分董事、高管未实施减持计划，投资者需关注公告内容

【要点概述】

• 成都圣诺生物科技股份有限公司（688117）于2026年3月23日公告，部分董事、高级管理人员在此前披露的减持计划期内，并未实施股份减持。
• 涉及两位高管：副总经理马中刚先生和董事/副总经理/财务负责人伍利先生。
• 两位高管原计划各自减持不超过18,816股，合计不超过公司总股本的0.0240%，但最终未减持任何股份。
• 减持计划的时间区间为2025年12月23日至2026年3月22日，现已到期。
• 两位高管均通过员工持股平台海南圣诺企业管理中心（有限合伙）间接持有公司股份，部分股份来自IPO前取得，部分来自2023年限制性股票激励计划。

【详细解读】

一、减持计划的背景与原定方案

• 马中刚先生持有175,616股（0.1116%），其中156,800股为IPO前取得，18,816股为2023年激励计划获得。
• 伍利先生持有116,816股（0.0742%），其中98,000股为IPO前取得，18,816股为2023年激励计划获得。
• 两位高管此前于2025年12月1日公告，因个人资金需求计划减持各18,816股，减持方式为集中竞价或大宗交易，减持期为公告披露15个交易日后3个月内。

二、实际减持结果及原因

• 截至2026年3月22日，减持期已到，两位高管均未减持任何股份。
• 减持区间内，减持数量为0，减持比例为0%，未产生任何减持成交金额。
• 公司解释未实施减持的原因系基于个人及市场情况考虑。
• 减持计划严格遵守相关法律法规和交易所业务规则，未出现提前终止计划或违反承诺情形。

三、对投资者和股价的潜在影响分析

• 未实施减持对市场情绪的正面影响： 原计划减持虽然数量有限，但高管未实际减持，显示其对公司未来发展的信心，或能提振市场情绪，有助于稳定股价。
• 减持信息透明： 及时披露减持计划及实际结果，体现公司治理规范，有利于投资者信心。
• 潜在关注点： 高管个人资金需求仍可能在未来一段时间内转化为减持行为，投资者宜持续关注后续公告。

【结语】

总体来看，圣诺生物本次公告内容显示，两位重要高管虽有减持计划，但最终未实际减持，对公司短期股价影响偏正面。投资者可关注后续高管持股变动及公司基本面进展。

免责声明： 本文内容仅供投资者参考，不构成任何投资建议。股市有风险，投资需谨慎。

English Version

Saintno Biotech: Key Directors and Executives Did Not Reduce Shares as Planned—What Investors Need to Know

Key Points

• Chengdu Saintno Biotech Co., Ltd. (688117) announced on March 23, 2026, that certain directors and senior executives did not carry out their previously disclosed share reduction plan during the scheduled period.
• Involved: Deputy General Manager Mr. Zhonggang Ma and Director/Deputy GM/CFO Mr. Li Wu.
• Both executives originally planned to each sell no more than 18,816 shares (total no more than 0.0240% of company capital), but in fact, did not reduce any shares.
• The planned reduction window was from December 23, 2025 to March 22, 2026, which has now expired.
• The shares held by these executives are partly from pre-IPO allotment and partly from the 2023 restricted stock incentive plan, held via the employee holding platform Hainan Saintno Enterprise Management Center (Limited Partnership).

Detailed Interpretation

I. Background and Original Reduction Plan

• Mr. Ma held 175,616 shares (0.1116%), with 156,800 shares from pre-IPO and 18,816 shares from the 2023 incentive plan.
• Mr. Wu held 116,816 shares (0.0742%), with 98,000 shares from pre-IPO and 18,816 shares from the 2023 incentive plan.
• On December 1, 2025, both executives announced for personal funding needs, they intended to reduce up to 18,816 shares each via block or auction, with the reduction period set as three months after 15 trading days from announcement.

II. Actual Outcome and Reasons

• As of March 22, 2026, the reduction window ended with neither executive selling any shares.
• Reduction quantity was zero, reduction ratio was zero, no sale proceeds were realized.
• The company explained the non-implementation was due to personal and market considerations.
• The reduction plan fully complied with applicable laws and exchange rules; no early termination or breach of commitments occurred.

III. Potential Impact on Investors and Share Price

• Positive Market Signal: Although the intended reduction was small, executives not selling may indicate confidence in the company’s future, potentially supporting share price stability.
• Transparency: Timely disclosure of both the reduction plan and actual outcome reflects robust corporate governance and may boost investor confidence.
• Ongoing Watch Points: As the executives’ personal funding needs persist, future reductions are possible—investors should monitor subsequent disclosures.

Conclusion

Overall, Saintno Biotech’s latest disclosure that key executives did not reduce shares as planned is a mildly positive signal for the stock in the short term. Investors are advised to monitor any future changes in executive shareholding and the company’s fundamental performance.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Stock investments carry risks; please act prudently.

View 圣诺生物 Historical chart here